Medical Oncology

, Volume 27, Issue 2, pp 199–202 | Cite as

Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

  • Bülent KaragözEmail author
  • Oğuz Bilgi
  • Ahmet Alacacıoğlu
  • Alpaslan Özgün
  • Özkan Sayan
  • Alev Akyol Erikçi
  • Emin Gökhan Kandemir
Original Paper


Aim To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment. Methods In this retrospective study, 46 postmenopausal women (20 with tmx and 26 with anastrazole) with breast cancer who received adjuvant hormone therapy were enrolled. The biochemical and complete blood count (CBC) parameters were documented before hormone treatment start and after 1 year. Results The lymphocyte count was higher after tmx use, but not anastrazole. Total white blood cells were increased both after 1-year tmx and anastrazole using. Mean platelet volume (MPV) increased after tmx use (8.2 ± 0.94–8.97 ± 0.97; P: 0.041), while it was not different after anastrazole use (7.96 ± 1.08–7.89 ± 0.99; P: 0.585). Other platelet parameters did not alter with tmx or anastrazole treatment. Conclusion We found increased MPV after tmx treatment, but did not after anastrazole treatment. The advanced studies which explore biological significance of high MPV in breast cancer patients used endocrine therapy, should be established.


Mean platelet volume Anastrazole Tamoxifen Platelets 


  1. 1.
    O’Regan RM, Gradishar WJ. Selective estrogen-receptor modulators in 2001. Oncology (Williston Park). 2001;15:1177–90.Google Scholar
  2. 2.
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–29. doi: 10.1056/NEJMra022219.CrossRefPubMedGoogle Scholar
  3. 3.
    Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001;28:291–304. doi: 10.1016/S0093-7754(01)90122-8.CrossRefPubMedGoogle Scholar
  4. 4.
    Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881–94.PubMedGoogle Scholar
  5. 5.
    Gradishar WJ, Jordan VC. Hormonal therapy for breast cancer. An update. Hematol Oncol Clin North Am 1999; 13:435-55, vii. doi: 10.1016/S0889-8588(05)70064-2.CrossRefPubMedGoogle Scholar
  6. 6.
    Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439–49. doi: 10.1002/cncr.20347.CrossRefPubMedGoogle Scholar
  7. 7.
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi: 10.1016/S1470-2045(07)70385-6.CrossRefPubMedGoogle Scholar
  8. 8.
    Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1983;53:503–11. doi: 10.1111/j.1365-2141.1983.tb02052.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32:443–60. doi: 10.1016/0049-3848(83)90255-4.CrossRefPubMedGoogle Scholar
  10. 10.
    Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409–11. doi: 10.1016/0140-6736(91)92719-I.CrossRefPubMedGoogle Scholar
  11. 11.
    Muscari A, Puddu GM, Cenni A, Silvestri MG, Giuzio R, Rosati M, Santoro N, Bianchi G, Magalotti D, Zoli M. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res 2008 (in press).Google Scholar
  12. 12.
    Grey AB, Evans MC, Kyle C, Reid IR. The anti-oestrogen tamoxifen produces haemodilution in normal postmenopausal women. J Intern Med. 1997;242:383–8. doi: 10.1046/j.1365-2796.1997.00227.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996;156:1806–10. doi: 10.1001/archinte.156.16.1806.CrossRefPubMedGoogle Scholar
  14. 14.
    Ranganath LR, Christofides J, Semple MJ. Increased mean platelet volume after oestrogen replacement therapy. Ann Clin Biochem. 1996;33(Pt 6):555–60.PubMedGoogle Scholar
  15. 15.
    Butterworth RJ, Bath PM. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets. 1998;9:359–64. doi: 10.1080/09537109876429.CrossRefPubMedGoogle Scholar
  16. 16.
    Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404. doi: 10.1046/j.1365-2141.2002.03441.x.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Bülent Karagöz
    • 1
    Email author
  • Oğuz Bilgi
    • 1
  • Ahmet Alacacıoğlu
    • 1
  • Alpaslan Özgün
    • 1
  • Özkan Sayan
    • 2
  • Alev Akyol Erikçi
    • 2
  • Emin Gökhan Kandemir
    • 1
  1. 1.GATA Haydarpasa Training Hospital Department of Medical OncologyHaydarpaşa, İstanbulTurkiye
  2. 2.GATA Haydarpasa Training Hospital Department of HematologyHaydarpaşa, İstanbulTurkiye

Personalised recommendations